RESUMO
It has been demonstrated that there is an association between serum lipoproteins and survival rate in patients with ischemic cardiomyopathy, as well as in patients with non-ischemic causes of heart failure. We tested the hypothesis of an association between serum lipoprotein levels and prognosis in a cohort of outpatients with heart failure, including Chagas' heart disease. The lipid profile of 833 outpatients with heart failure in functional classes III and IV of the New York Heart Association, with a mean age of 46.9 ± 10.6 years, 655 (78.6 percent) men and 178 (21.4 percent) women, was studied from April 1991 to June 2003. The survival rate was estimated by the Kaplan-Meyer's method and the Cox proportional hazards models. Etiology of heart failure was ischemic cardiomyopathy in 171 (21 percent) patients, Chagas' heart disease in 144 (17 percent), hypertensive cardiomyopathy in 136 (16 percent), and other etiologies in 83 (10 percent). In 299 (36 percent) patients, heart failure was ascribed to idiopathic dilated cardiomyopathy. Variables significantly associated with mortality were age (hazard ratio, HR = 1.02; 95 percentCI = 1.01-1.03; P = 0.0074), male gender (HR = 1.77; 95 percentCI = 1.2-2.62; P = 0.004), idiopathic dilated cardiomyopathy (HR = 1.81; 95 percentCI = 1.16-2.82; P = 0.0085), serum triglycerides (HR = 0.97; 95 percentCI = 0.96-0.98; P < 0.0001), and HDL cholesterol (HR = 0.99; 95 percentCI = 0.99-1.0; P = 0.0280). Therefore, higher serum HDL cholesterol and higher serum triglycerides were associated with lower mortality in this cohort of outpatients with heart failure.
Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , HDL-Colesterol/sangue , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/mortalidade , Triglicerídeos/sangue , Estudos de Coortes , Insuficiência Cardíaca/etiologia , Prognóstico , Índice de Gravidade de Doença , Análise de Sobrevida , Adulto JovemRESUMO
It has been demonstrated that there is an association between serum lipoproteins and survival rate in patients with ischemic cardiomyopathy, as well as in patients with non-ischemic causes of heart failure. We tested the hypothesis of an association between serum lipoprotein levels and prognosis in a cohort of outpatients with heart failure, including Chagas' heart disease. The lipid profile of 833 outpatients with heart failure in functional classes III and IV of the New York Heart Association, with a mean age of 46.9 +/- 10.6 years, 655 (78.6%) men and 178 (21.4%) women, was studied from April 1991 to June 2003. The survival rate was estimated by the Kaplan-Meyer's method and the Cox proportional hazards models. Etiology of heart failure was ischemic cardiomyopathy in 171 (21%) patients, Chagas' heart disease in 144 (17%), hypertensive cardiomyopathy in 136 (16%), and other etiologies in 83 (10%). In 299 (36%) patients, heart failure was ascribed to idiopathic dilated cardiomyopathy. Variables significantly associated with mortality were age (hazard ratio, HR = 1.02; 95%CI = 1.01-1.03; P = 0.0074), male gender (HR = 1.77; 95%CI = 1.2-2.62; P = 0.004), idiopathic dilated cardiomyopathy (HR = 1.81; 95%CI = 1.16-2.82; P = 0.0085), serum triglycerides (HR = 0.97; 95%CI = 0.96-0.98; P < 0.0001), and HDL cholesterol (HR = 0.99; 95%CI = 0.99-1.0; P = 0.0280). Therefore, higher serum HDL cholesterol and higher serum triglycerides were associated with lower mortality in this cohort of outpatients with heart failure.
Assuntos
HDL-Colesterol/sangue , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/mortalidade , Triglicerídeos/sangue , Adulto , Idoso , Estudos de Coortes , Feminino , Insuficiência Cardíaca/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Índice de Gravidade de Doença , Análise de Sobrevida , Adulto JovemRESUMO
Myocyte diameter, fractional area of collagen, intensity of myocarditis and parasite persistence (explored by immunohistochemistry and PCR) were evaluated in serial sections of endomyocardial biopsies from 29 outpatients with chronic chagasic cardiopathy. The patients, 25 males and four females with a mean (S.D.) age of 43 (9) years, were subsequently followed up for 3-2861 days (median=369 days). During this follow-up, 16 (55%) of the patients died. The biopsies revealed myocarditis in 25 (86%) of the patients and high-grade myocarditis in 14 (56%). Although immunohistochemistry failed to demonstrate Trypanosoma cruzi antigens in any of the samples, five (33%) of the 15 biopsies successfully tested in the PCR-based assay for T. cruzi DNA were found positive, indicating parasite persistence. There was a significant positive association between myocardial parasite persistence and high-grade myocarditis (P=0.014); five (71%) of the seven endomyocardial biopsies with high-grade myocarditis that were successfully tested in the PCR assays showed persistent T. cruzi DNA. The survival time of the patients was not, however, found to be significantly associated with myocardial parasite persistence, any of the morphometric measurements taken, or the presence or intensity of myocarditis.
Assuntos
Cardiomiopatia Chagásica/parasitologia , Doença de Chagas/parasitologia , Miocardite/parasitologia , Miocárdio , Trypanosoma cruzi/imunologia , Adulto , Animais , Antígenos de Protozoários/análise , Biópsia , Cardiomiopatia Chagásica/imunologia , Cardiomiopatia Chagásica/patologia , Doença de Chagas/imunologia , Doença de Chagas/patologia , Doença Crônica , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Miocardite/imunologia , Miocardite/patologia , Miocárdio/patologia , Reação em Cadeia da PolimeraseRESUMO
Iron depletion was suggested to be protective against the development of ischemic heart disease. Population studies have led to conflicting results, and such an association has not been addressed in patients with heart failure due to cardiomyopathy. We studied the distribution of hemochromatosis-related mutations in 319 patients with heart failure due to cardiomyopathy of different etiologies. The genotypic distribution showed a significantly higher prevalence of heterozygotes for the C282Y mutation in patients with ischemic cardiomyopathy than in patients with cardiomyopathy of nonischemic etiologies (p = 0.0036). The frequency of the D63 mutation was not significantly different between ischemic versus nonischemic groups. In multiple logistic regression models adjusted for age, sex, ethnicity, and different degrees of disease progression, there was a strong and significant association of the C282Y mutation with ischemic cardiomyopathy compared with the nonischemic group (odds ratio 6.64, 95% confidence interval 1.71 to 25.73, after adjustment). In our sample, genetic variation in the HFE gene was associated with ischemic cardiomyopathy. Such association merits further study regarding its value as a prognostic marker in patients with ischemic heart disease.
Assuntos
Cardiomiopatias/complicações , Hemocromatose/genética , Mutação de Sentido Incorreto , Adolescente , Adulto , Idoso , Ácido Aspártico/genética , Cisteína/genética , Progressão da Doença , Feminino , Genótipo , Insuficiência Cardíaca/etiologia , Hemocromatose/complicações , Histidina/genética , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Prognóstico , Tirosina/genéticaRESUMO
OBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43 +/- 9 years), and their left ventricular ejection fraction varied from 8% to 35%. Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients. The initial dose of carvedilol was 12.5 mg, which was increased weekly until it reached 75 mg/day, according to the patient's tolerance. Clinical assessment, electrocardiogram, echocardiogram, and radionuclide ventriculography were performed in the pretreatment phase, being repeated after 2 and 6 months of medication use. RESULTS: A reduction in heart rate (p = 0.016) as well as an increase in left ventricular shortening fraction (p = 0.02) and in left ventricular ejection fraction (p = 0.017) occurred in the group using carvedilol as compared with that using placebo. CONCLUSION: Carvedilol added to the usual therapy for heart failure resulted in better heart function.
Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Carbazóis/uso terapêutico , Baixo Débito Cardíaco/tratamento farmacológico , Cardiomiopatia Dilatada/complicações , Frequência Cardíaca/efeitos dos fármacos , Propanolaminas/uso terapêutico , Volume Sistólico/efeitos dos fármacos , Adulto , Idoso , Baixo Débito Cardíaco/etiologia , Carvedilol , Método Duplo-Cego , Feminino , Ventrículos do Coração/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE: To evaluate patient selection for heart transplantation or dynamic cardiomyoplasty. METHODS: We evaluated 380 patients from April 1991 to July 1993. The ages ranged between 16 and 68 (mean 43.5 +/- 11.46) years, 303 (79.7%) were male. The diagnoses were dilated cardiomyopathy in 163 (42.9%), Chagas' cardiomyopathy in 70 (18.4%), ischemic heart disease in 61 (16.1%), hypertensive heart disease in 40 (10.5%), valvular heart disease in 23 (6.1%), alcoholic cardiomyopathy in 12(3.2%), peripartum cardiomyopathy in 5 (1.3%) and myocarditis of unknown etiology in 5 (1.3%). RESULTS: The indication of heart transplantation was eventually done in 55 (14.4%), and 19 (5%) were submitted to transplantation. Dynamic cardiomyoplasty was indicated in 9 (2.3%) patients and was performed in 8 (2.1%). In 30 (7.8%) patients there were clinical contraindications for transplantation. Conventional surgical treatment was indicated for 12 (3.1%) patients: myocardial revascularization and/or ventricular aneurismectomy in 5, surgical treatment of valvular heart disease in 6 and of atrial fibrillation in 1. Socioeconomic limitations precluded transplantation in 43 (11.3%) and psychic limitations hindered transplantation in 23 (6.0%) patients. Refusal of procedure by the patient occurred in 10 (2.6%) cases. Improvement of the symptoms occurred in 69 (18.1%) patients. CONCLUSION: A small percentage of patients are eligible and are eventually submitted to heart transplantation or dynamic cardiomyoplasty. New strategies may be delineated during follow up, as deferring transplantation or conventional surgical treatment of ischemic or valvular heart disease. Sociopsychic evaluation is an important step in the care of the patients.